Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues (fourth edition). Who Classification of Tumours, Volume 2, 2008.
Kiesewetter B, Raderer M. Antibiotic therapy in nongastrointestinal MALT lymphoma: A review of the literature. Blood 2013; 122:1350-7.
Zucca E, Copie-Bergman C, Ricardi U, et al. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl. 6):vi144-8.
Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): A model for mature Bcell neoplasms. Blood 2005; 105:2274-80.
Oh SY, Suh C. Non-gastric marginal zone B-cell lymphoma in Korea: Clinical features, treatment, and prognostic factors. Korean J Intern Med 2010; 25:227-36.
Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus conferences: Guidelines on malignant lymphoma. Part 2: Marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24:857-77.
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 2014; 32: 3059-68.
Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32:3048-58.
Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: Analysis of the surveillance, epidemiology, and end results database. Cancer 2013; 119:629-38.
Thieblemont C. Clinical presentation and management of marginal zone lymphomas. Hematology. Am Soc Hematol Educ Program 2005; 307-13.
Thieblemont C, Conconi A, Tucci A, et al. A simple and effective malt lymphoma-specific progostic index generated from the dataset of the IESLG-19 controled clinical trial (abstract). Hematol Oncol 2015; 33:167-8.
O'Connor A, Vaira D, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2014. Helicobacter 2014; 19(Suppl. 1):38-45.
Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 2012; 61:646-64.
Ferreri AJ, Govi S, Pasini E, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: Final results of an international phase II trial. J Clin Oncol 2012; 30: 2988-94.
Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior eventfree survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol 2013; 31: 565-72.
Wilcox RA. Cutaneous B-cell lymphomas: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88:73-6.
Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood 2008; 112:4824-31.
Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-10.
Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 2013; 31:1506-13.
van den Brand M, van Krieken JH. Recognizing nodal marginal zone lymphoma: Recent advances and pitfalls. A systematic review. Haematologica 2013; 98:1003-13.
Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104:1258-65.
Lopez-Guillermo A, Montserrat E, Bosch F, et al. Applicability of the International index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12:1343-8.
Algara P, Mateo MS, Sanchez-Beato M, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 2002; 99:1299-304.
Chacon JI, Mollejo M, Munoz E, et al. Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002; 100:1648-54.
Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma: Proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 2005; 106:1831-8.
Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008; 22:487-95.
Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347:89-94.
Bennett M, Schechter GP. Treatment of splenic marginal zone lymphoma: Splenectomy versus rituximab. Semin Hematol 2010; 47:143-7.
Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006; 107:125-35.
